Trelagliptin succinate is primarily used in the management of type 2 diabetes mellitus. It functions as a dipeptidyl peptidase-4 (DPP-4) inhibitor, which helps regulate blood glucose levels by increasing the activity of incretin hormones. These hormones stimulate insulin release and reduce glucagon secretion, particularly after meals. Its long-acting formulation allows for once-weekly dosing, improving patient adherence and convenience. It is often prescribed as part of a comprehensive treatment plan that includes diet, exercise, and other medications to achieve optimal glycemic control. It is particularly beneficial for patients who require a stable and sustained therapeutic effect with minimal dosing frequency.